

Tuberculosis profile: Maldives

Population 2021: 0.52 million

Estimates of TB burden*, 2021

	Number	(Rate per 100 000 population)
Total TB incidence	200 (150-250)	38 (29-48)
HIV-positive TB incidence	0 (0-2)	0 (0-0.45)
MDR/RR-TB incidence**	2 (0-4)	0.37 (0-0.78)
HIV-negative TB mortality	11 (10-12)	2.1 (1.9-2.3)
HIV-positive TB mortality	0 (0-0)	0 (0-0)

Estimated proportion of TB cases with MDR/RR-TB*, 2021

New cases	0.8% (0.16-2.1)
Previously treated cases	6.2% (0.4-25)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2021	44% (35-58)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2021	6% (4-7)

TB case notifications, 2021

Total new and relapse	87
- % tested with rapid diagnostics at time of diagnosis	53%
- % with known HIV status	0%
- % pulmonary	55%
- % bacteriologically confirmed [^]	100%
- % children aged 0-14 years	3%
- % women (aged ≥15 years)	46%
- % men (aged ≥15 years)	51%
Total cases notified	87

TB/HIV care in new and relapse TB patients, 2021

	Number	(%)
Patients with known HIV status who are HIV-positive	0	
- on antiretroviral therapy	0	

Drug-resistant TB care**, 2021

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases [^]	96%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases [^]	
Laboratory-confirmed cases - MDR/RR-TB ^{^^}	0
Patients started on treatment - MDR/RR-TB ^{^^^}	0
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^{^^}	0
Patients started on treatment - pre-XDR-TB or XDR-TB ^{^^^}	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	0

Treatment success rate and cohort size


	Success	Cohort
New and relapse cases registered in 2020	80%	107
Previously treated cases, excluding relapse, registered in 2020		0
HIV-positive TB cases registered in 2020		0
MDR/RR-TB cases started on second-line treatment in 2019	0%	1
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2019		0

TB preventive treatment, 2021


% of HIV-positive people (newly enrolled in care) on preventive treatment	0%
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	0% (0-0)

* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.
 ** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone
[^] Calculated for pulmonary cases only
^{^^} Includes cases with unknown previous TB treatment history
^{^^^} Includes patients diagnosed before 2021 and patients who were not laboratory-confirmed


Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)



HIV-negative TB mortality (Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2021 (Number)



Cases attributable to five risk factors, 2021 (Number)

